Nuziveedu Seeds Ltd. & Ors. v. Monsanto Technology LLC & Ors., FAO (OS) (COMM) 86/2017 & 76/2017, Delhi High Court, decided on 11 April 2018.
Background
This case arose from a long-standing dispute between Monsanto Technology LLC and Indian seed companies led by Nuziveedu Seeds Ltd. Monsanto held Indian Patent No. 214436, which related to a synthetic nucleic acid sequence (Cry2Ab gene) inserted into cotton plants to confer resistance against bollworms. This technology was commercially known as Bollgard-II (Bt. cotton technology). Monsanto licensed this technology to Indian seed companies through sub-license agreements. These companies received donor Bt. cotton seeds and were required to pay a “trait fee” (royalty) for incorporating the Bt. trait into their own cotton hybrids through breeding processes.
Disputes arose when the Government of India introduced the Cotton Seeds Price (Control) Order, 2015, which regulated the maximum sale price of Bt. cotton seeds and effectively reduced the payable trait value. Nuziveedu refused to pay royalties beyond the government-fixed amount. Monsanto terminated the licensing agreements and sued for patent infringement and trademark infringement, alleging unauthorized use of its patented technology. In response, Nuziveedu challenged the very validity of Monsanto’s patent, arguing that it fell within the exclusion under Section 3(j) of the Patents Act, 1970, which prohibits patenting of plants, seeds, varieties, and essentially biological processes. The Division Bench of the Delhi High Court decided to finally determine the question of patentability at the appellate stage.
Issue for Determination
The central issue before the Court was whether Monsanto’s patent claims – particularly those relating to the nucleic acid sequence and its insertion into plant cells – were patentable under Indian law or whether they were barred by Section 3(j) of the Patents Act. Closely connected to this was the issue of whether such protection should instead fall exclusively under the Protection of Plant Varieties and Farmers’ Rights Act, 2001 (PV Act), which provides a sui generis regime for plant variety protection. The Court also had to consider whether Monsanto could enforce patent rights over transgenic cotton seeds developed by Nuziveedu after termination of the licensing agreements.
Key Holding of the Court
The Division Bench held that Monsanto’s patent, though framed as relating to a synthetic nucleic acid sequence and method of insertion, effectively resulted in a transgenic plant and became inseparable from the plant once integrated into its genome. The Court concluded that once the gene is introgressed into a plant and expressed in the seed, it becomes part of the plant. Therefore, the patent claim in substance related to “plants or parts thereof” and was hit by the exclusion under Section 3(j) of the Patents Act. The Court further held that permitting such patent claims would indirectly allow patenting of seeds and plant varieties, which the statute clearly prohibits. The proper regime for protection of plant varieties, including transgenic varieties, is the Protection of Plant Varieties and Farmers’ Rights Act, 2001. Accordingly, the Court held that Monsanto’s patent could not be sustained in respect of the transgenic cotton varieties and the enforcement action based on that patent could not proceed in its existing form.
Statutory Provisions Involved
Patents Act, 1970, Section 2(1)(j) – Defines “invention.” Section 3(j) Excludes from patentability “plants and animals in whole or any part thereof other than microorganisms but including seeds, varieties and species and essentially biological processes for production or propagation of plants and animals.” Section 48 Grants exclusive rights to the patentee.
Protection of Plant Varieties and Farmers’ Rights Act, 2001,Section 2(za) Defines “variety,” including transgenic varieties. Section 26 – Provides for benefit sharing. Section 30 – Recognizes researchers’ rights. Section 39 – Protects farmers’ rights to save, use, exchange and sell seeds. Section 92 – Gives overriding effect to the PV Act over inconsistent laws. The Court harmonized these statutes and held that plant-related genetic innovations fall within the domain of the PV Act rather than patent law.
Doctrinal Significance
This judgment is doctrinally significant for several reasons.
First, it provides an authoritative interpretation of Section 3(j) and clarifies that patentability must be determined not merely by the drafting of claims but by their substantive effect. Even if an invention is framed as a “nucleic acid sequence,” it cannot escape exclusion if its practical outcome is a patented plant or seed.
Second, the decision reinforces India’s restrictive approach toward patenting life forms and affirms legislative intent to exclude plants and seeds from patent monopolies.
Third, the case draws a clear boundary between the Patents Act and the Protection of Plant Varieties and Farmers’ Rights Act, emphasizing that India has consciously adopted a sui generis system for plant protection under the PV Act in compliance with TRIPS obligations.
Finally, the judgment reflects a policy-oriented approach that balances innovation incentives with agricultural sovereignty, breeders’ rights and farmers’ rights. It underscores that biotechnology patents in India cannot override the statutory protections built into the PV Act framework.